Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Anticonvulsant

or [[:Category:Antifungals|Antifungal (imidazole)]]

Use the filters below to narrow your results.

Brivaracetam (1) · Butorphanol (1) · Cannabidiol (1) · Cenobamate (1) · Clobazam (1) · Clotrimazole (1) · Codeine (2) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Eslicarbazepine (1) · Ethosuximide (1) · Ethylmorphine (1) · Felbamate (1) · Fenfluramine (1) · Fentanyl (1) · Fosphenytoin (1) · Hydrocodone (1) · Hydromorphone (1) · Ketoconazole (1) · Lacosamide (1) · Levorphanol (1) · Meperidine (1) · Nalbuphine (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Perampanel (1) · Phenobarbital (1) · Phenytoin (1) · Rufinamide (1) · Stiripentol (1) · Tapentadol (1) · Tiagabine (1) · Valproic acid (1) · Vigabatrin (1) · Zonisamide (1)

None (5) · (multiple, generic dominant) (1) · Aptiom (1) · Banzel (1) · Briviact (1) · Cerebyx (1) · Darvon (1) · Demerol (1) · Depakote (1) · Diacomit (1) · Dilantin (1) · Dilaudid (1) · Duragesic (1) · Epidiolex (1) · Felbatol (1) · Fintepla (1) · Fycompa (1) · Gabitril (1) · Lotrimin, Mycelex, Gyne-Lotrimin; OTC widely (1) · Luminal (1) · Nizoral (oral discontinued in US for most fungal indications; topical still widely available) (1) · Nubain (1) · Nucynta (1) · Onfi (1) · Opana (1) · Sabril (1) · Stadol (1) · Talwin (1) · Vicodin (1) · Vimpat (1) · Xcopri (1) · Zarontin (1) · Zonegran (1)

None (2) · AMPA receptor antagonist (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug of phenytoin; sodium channel blocker (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Serotonin releaser; sigma-1 agonist (1) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1)

None (34) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000884-QINU`"', '"`UNIQ--vote-00000885-QINU`"', '"`UNIQ--vote-00000886-QINU`"', '"`UNIQ--vote-00000887-QINU`"' (1) · '"`UNIQ--vote-00000F40-QINU`"', '"`UNIQ--vote-00000F41-QINU`"', '"`UNIQ--vote-00000F42-QINU`"', '"`UNIQ--vote-00000F43-QINU`"', '"`UNIQ--vote-00000F44-QINU`"' (1)

None (34) · Adult: 15–60 mg every 4 hours as needed. (1) · Topical 2% shampoo twice weekly for seborrheic dermatitis or tinea versicolor; oral use restricted by 2013 FDA action to indications where alternatives have failed (1) · Topical: 1% cream BID × 2-4 weeks; vaginal: 1% or 2% cream nightly × 7 days, or 100/200/500 mg vaginal tablet single or 3-day regimens; troche: 10 mg PO five times daily × 2 weeks for thrush (1)

None (34) · 1% (OTC), 2% (Rx) shampoo; 2% cream; 2% gel; 200 mg oral tablet (rarely used now) (1) · 1% topical cream, lotion, solution; 1%, 2% vaginal cream; 100, 200, 500 mg vaginal tablets; 10 mg oral troches; combination with betamethasone (Lotrisone, Rx) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (34) · 360 mg/day (1) · Topical: BID; troche: 5×/day (1) · Topical: regimen-specific; oral: 400 mg/d in remaining specialty indications (1)

None (34) · gel); oral (restricted) (1) · oral troche (1) · PO (only formulation marketed in the US). (1) · shampoo (1) · Topical (1) · Topical (cream (1) · vaginal (1)

None (34) · 30–60 min (PO) (1) · Days (1) · Topical hours; oral days (1)

None (34) · 4–6 hours (1) · Hours per application (1) · Hours per application (topical); 24 hours (oral) (1)

None (34) · 2.5–3 hours (1) · Not meaningfully described (minimal systemic absorption from topical use)'"`UNIQ--ref-00000F45-QINU`"' (1) · Topical: not meaningfully described; oral 2-8 hours'"`UNIQ--ref-00000888-QINU`"' (1)

None (34) · Topical: minimal systemic; oral: pH-dependent, requires gastric acid'"`UNIQ--ref-00000889-QINU`"' (1) · Topical: minimal systemic; troche: ~3% systemic'"`UNIQ--ref-00000F46-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (34) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Topical and vaginal generally considered safe; widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Topical generally safe; oral avoided.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (34) · OTC (1% shampoo) and [[USLegal:Prescription only|Rx-only]] (higher strengths, oral) in US. Oral form carries a '''Boxed Warning''' for hepatotoxicity and is restricted by FDA to refractory fungal infections where no alternatives are available (1) · OTC (lower strengths) and [[USLegal:Prescription only|Rx-only]] (combination with betamethasone) in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)